Immunization against bovine herpesvirus-1 infection. Preliminary tests in calves with a DNA vaccine.
A bovine herpesvirus-1 (BHV-1) vaccine expressing glycoprotein D, the form with the transmembrane anchor removed, was evaluated for inducing immunity in calves. The plasmid encoding gD of BHV-1 was injected three times to nine calves, using three animals for each of the following routes: intramuscularly (i.m.), intradermally (i.d.), or intranasally (i.n.). Three additional calves were given the plasmid vector only and served as unvaccinated controls. When calves were subjected to challenge infection with BHV-1, all vaccinated calves as well as the controls developed a typical severe form of infectious bovine rhinotracheitis. However, compared to the controls, the vaccinated calves showed earlier clearance of challenge virus. Moreover, the calves given the vaccine i.m. developed neutralizing antibody to BHV-1 between 21 and 42 days following the first injection of vaccine, whereas in calves vaccinated either i.d. or i.n., as well as the controls, antibody first appeared in their sera 14 days post-challenge infection.
Castrucci
G
G
Laboratory of Virology V.Cilli, Department of Technology and Biotechnology of Animal Productions, University of Perugia, Via S. Costanzo 4, 06126 Perugia, Italy.
Ferrari
M
M
Marchini
C
C
Salvatori
D
D
Provinciali
M
M
Tosini
A
A
Petrini
S
S
Sardonini
Q
Q
Lo Dico
M
M
Frigeri
F
F
Amici
A
A
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002417:Cattle; D002418:Cattle Diseases / Q000276:immunology / Q000517:prevention & control / Q000821:virology*; D006566:Herpesviridae Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary* / Q000821:virology; D007242:Herpesvirus 1, Bovine / Q000276:immunology*; D007114:Immunization / Q000662:veterinary*; D009500:Neutralization Tests / Q000662:veterinary; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000009:adverse effects / Q000235:genetics / Q000276:immunology; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000235:genetics / Q000276:immunology
D000914:Antibodies, Viral; D019444:Vaccines, DNA; D014764:Viral Proteins; D014765:Viral Vaccines; C046998:bovine herpesvirus type-1 glycoproteins